RCKT Rocket Pharmaceuticals, Inc. Stock Quote

RCKT [NASD]

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	0.20%	Shs Outstand	55.19M	Perf Week	-3.29%
Market Cap	3.52B	Forward P/E	-	EPS next Y	-2.14	Insider Trans	180.46%	Shs Float	37.57M	Perf Month	-5.98%
Income	-98.60M	PEG	-	EPS next Q	-0.51	Inst Own	92.70%	Short Float	24.57%	Perf Quarter	88.92%
Sales	-	P/S	-	EPS this Y	16.70%	Inst Trans	0.37%	Short Ratio	13.43	Perf Half Y	129.47%
Book/sh	4.38	P/B	12.57	EPS next Y	-10.90%	ROA	-27.50%	Target Price	70.50	Perf Year	156.64%
Cash/sh	3.57	P/C	15.40	EPS next 5Y	10.80%	ROE	-35.80%	52W Range	9.01 - 63.99	Perf YTD	0.38%
Dividend	-	P/FCF	-	EPS past 5Y	14.60%	ROI	-	52W High	-13.97%	Beta	1.94
Dividend %	-	Quick Ratio	7.30	Sales past 5Y	-	Gross Margin	-	52W Low	510.99%	ATR	4.77
Employees	84	Current Ratio	7.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	54.12	Volatility	6.39% 7.54%
Optionable	Yes	Debt/Eq	0.28	EPS Q/Q	-37.60%	Profit Margin	-	Rel Volume	0.85	Prev Close	58.37
Shortable	Yes	LT Debt/Eq	0.25	Earnings	Nov 05 BMO	Payout	-	Avg Volume	687.16K	Price	55.05
Recom	1.80	SMA20	-2.61%	SMA50	24.33%	SMA200	97.97%	Volume	582,272	Change	-5.69%

Dec-16-20

Initiated

UBS

Buy

$75

Dec-08-20

Downgrade

Oppenheimer

Outperform → Perform

Jul-02-20

Initiated

JP Morgan

Overweight

Jun-25-20

Resumed

BofA/Merrill

Buy

$34

Jun-01-20

Resumed

Oppenheimer

Outperform

Nov-06-19

Initiated

Chardan Capital Markets

Buy

$30

Sep-26-19

Initiated

Piper Jaffray

Overweight

Apr-23-19

Initiated

Robert W. Baird

Outperform

Mar-15-19

Initiated

BofA/Merrill

Buy

$27

Feb-05-19

Initiated

Oppenheimer

Outperform

$39

Sep-13-18

Initiated

Ladenburg Thalmann

Buy

$30

Jul-10-18

Initiated

William Blair

Outperform

Jan-15-21 08:30PM	W.R. Grace, GameStop See Activist Action Barrons.com -5.69%
Jan-11-21 07:00AM	Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline Business Wire
Jan-06-21 07:00AM	Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-18-20 12:10AM	Is RCKT A Good Stock To Buy Now? Insider Monkey
Dec-14-20 04:01PM	Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire -5.88%
Dec-10-20 10:52AM	Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data Zacks
07:42AM	The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga
Dec-09-20 11:32PM	Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock Business Wire +83.39%
06:01PM	These Biotech Stock Market Winners Have Nothing to Do With COVID-19 Motley Fool
04:26PM	Rocket Pharmaceuticals Surges To 5-Year High On Promising Gene Therapy Investor's Business Daily
07:51AM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
07:23AM	The Daily Biotech Pulse: Roche & Moderna Strike COVID Testing Partnership, Rocket Pharma's Gene Therapy Readout, Breast Cancer Presentations Benzinga
Dec-08-20 04:00PM	Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease Business Wire
Dec-07-20 02:30PM	Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting Business Wire
Dec-06-20 10:00AM	Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting Business Wire
Dec-02-20 07:00AM	Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual Meeting Business Wire
Nov-24-20 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Nov-13-20 07:00AM	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis Business Wire
Nov-04-20 10:37AM	Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting Business Wire +7.22%
07:00AM	Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Progress Business Wire
Oct-16-20 07:15AM	The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs Benzinga
07:00AM	Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting Business Wire
Oct-13-20 12:04PM	Here is What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
Oct-01-20 07:00AM	Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting Business Wire
Sep-24-20 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Sep-04-20 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Sep-02-20 07:00AM	Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease Business Wire
Aug-27-20 07:00AM	Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis Business Wire
Aug-26-20 07:00AM	Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of Excellence Business Wire
Aug-05-20 07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress Business Wire
Jul-13-20 07:00AM	Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Jul-08-20 12:53PM	J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels TipRanks +6.65%
Jun-29-20 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis Business Wire
Jun-27-20 03:16PM	Hedge Funds Arent Crazy About Rocket Pharmaceuticals, Inc. (RCKT) Anymore Insider Monkey
Jun-08-20 07:00AM	Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021 Business Wire
May-26-20 07:00AM	Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference Business Wire
May-12-20 07:00AM	Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
May-10-20 10:39PM	Was The Smart Money Right About Rocket Pharmaceuticals (RCKT)? Insider Monkey
May-06-20 07:00AM	Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress Business Wire
May-05-20 07:00AM	Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference Business Wire +9.18%
Apr-22-20 07:00AM	Rocket Pharmaceuticals Appoints Elisabeth Bjrk, M.D., Ph.D. to Board of Directors Business Wire
Apr-09-20 08:22AM	Rocket Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-02-20 09:00AM	Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic Business Wire +6.46%
Mar-27-20 10:04AM	Why Rocket (RCKT) Stock Might be a Great Pick Zacks -9.48%
Mar-19-20 07:00AM	Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease Business Wire +32.85%
Mar-05-20 07:00AM	Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights Business Wire
Feb-24-20 07:00AM	Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia Business Wire
Feb-18-20 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Feb-11-20 09:15AM	Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021 Business Wire
Feb-06-20 07:00AM	Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness Business Wire
Jan-09-20 09:44AM	What You Must Know About Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Beta Value Simply Wall St.
Jan-06-20 12:00PM	Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy Zacks
07:00AM	Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-29-19 03:24AM	Corporate Insiders Pull the Trigger on 3 Buy-Rated Stocks TipRanks
Dec-16-19 07:00AM	Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia Business Wire +7.26%
Dec-13-19 04:01PM	Rocket Pharmaceuticals Announces Closing of Public Offering Business Wire
12:37PM	Did Hedge Funds Drop The Ball On Rocket Pharmaceuticals, Inc. (RCKT) ? Insider Monkey
Dec-11-19 07:21AM	The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga -13.99%
Dec-10-19 10:45PM	Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire +5.44%
04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
12:00PM	Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy Zacks
07:56AM	The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-09-19 07:00AM	Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I Business Wire
Dec-08-19 06:00PM	Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 "Process B" for Fanconi Anemia at 61st American Society of Hematology Annual Meeting Business Wire
Dec-06-19 07:00AM	Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia Business Wire +13.47%
Dec-05-19 07:00AM	Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting Business Wire
Dec-04-19 09:27AM	Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue? Zacks
Nov-27-19 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences TEST Business Wire Releases
Nov-07-19 07:00AM	Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights Business Wire
Nov-06-19 09:00AM	Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting Business Wire
Nov-05-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit Business Wire
Nov-01-19 11:16AM	Should You Buy Rocket Pharmaceuticals, Inc. (RCKT)? Insider Monkey
Oct-24-19 07:00AM	Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 Process A for Fanconi Anemia Business Wire
Oct-22-19 07:00AM	Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Oct-15-19 07:00AM	Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress Business Wire +8.24%
Oct-01-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference Business Wire
Sep-23-19 07:00AM	Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Sep-10-19 07:00AM	Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine Business Wire +5.96%
Sep-04-19 07:00AM	Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting Business Wire
Aug-28-19 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Aug-22-19 07:00AM	Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia Business Wire
Aug-07-19 07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights Business Wire
Jul-31-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference Business Wire
Jun-25-19 09:24PM	Heres What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
11:30AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Simply Wall St.
Jun-18-19 07:00AM	Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome Business Wire
May-29-19 10:00AM	Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients Forum Business Wire
May-23-19 03:00PM	Did You Manage To Avoid Rocket Pharmaceuticals's (NASDAQ:RCKT) 19% Share Price Drop? Simply Wall St.
May-09-19 01:54PM	Heres What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
May-08-19 07:13AM	Rocket Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM	Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights Business Wire
May-07-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference Business Wire
May-02-19 07:00AM	Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting Business Wire
Apr-30-19 07:00AM	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM) Business Wire -6.31%
Apr-18-19 11:20AM	Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Apr-16-19 08:10AM	The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 10:36PM	Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire
04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
12:49PM	Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting Business Wire
Mar-15-19 08:00AM	Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting Business Wire +5.43%

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Kinnari	Chief Operating Officer	Dec 28	Sale	56.72	16,761	950,745	94,977	Dec 30 04:50 PM
RTW INVESTMENTS, LP	Director	Dec 10	Buy	56.00	247,720	13,872,320	17,530,044	Dec 14 07:19 PM
Shah Gaurav	President & CEO	Mar 24	Option Exercise	0.43	90,925	39,098	1,061,642	Mar 26 07:48 PM
Patel Kinnari	Chief Operating Officer	Mar 18	Buy	9.50	1,000	9,500	6,675	Mar 19 07:56 PM
Shah Gaurav	President & CEO	Feb 25	Option Exercise	0.43	290,000	125,628	976,950	Feb 27 05:36 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience